KIR2DL1
KIR2DL1 Molekülinformation
| Englischer Name | Killer cell immunoglobulin-like receptor 2DL1 | Anzahl der inverkehr gebrachten Arzneimittel | 0 |
| Anzahl der klinischen Arzneimittel | 1 | Target-Alias | KIR2DL1，NKAT-1，NKAT1，MHC class I NK cell receptor，Killer Cell Immunoglobulin Like Receptor， Two Ig Domains And Long Cytoplasmic Tail 1，Killer Cell Immunoglobulin-Like Receptor， Two Domains， Long Cytoplasmic Tail， 1，P58 Natural Killer Cell Receptor Clones CL-42/47.11，P58 Killer Cell Inhibitory Receptor KIR-K64，Natural Killer-Associated Transcript 1，P58.1 MHC Class-I-Specific NK Receptor，CD158 Antigen-Like Family Member A，P58 NK Receptor CL-42/47.11，CD158A，Killer Cell Immunoglobulin-Like Receptor 2DL1，P58 NK Cell Inhibitory Receptor NKR-K6，Killer Inhibitory Receptor 2-2-1，KIR2DL Protein，CD158a Antigen，KIR2DL1/3DL2，KIR-K64，KIR221，P58.1，NKAT，Receptors， KIR2DL1，Cl-42 |
| Höchste Forschungs- und Entwicklungsphase | Phase 2 Clinical | ||
| Englischer Name | Killer cell immunoglobulin-like receptor 2DL1 |
| Target-Alias | KIR2DL1，NKAT-1，NKAT1，MHC class I NK cell receptor，Killer Cell Immunoglobulin Like Receptor， Two Ig Domains And Long Cytoplasmic Tail 1，Killer Cell Immunoglobulin-Like Receptor， Two Domains， Long Cytoplasmic Tail， 1，P58 Natural Killer Cell Receptor Clones CL-42/47.11，P58 Killer Cell Inhibitory Receptor KIR-K64，Natural Killer-Associated Transcript 1，P58.1 MHC Class-I-Specific NK Receptor，CD158 Antigen-Like Family Member A，P58 NK Receptor CL-42/47.11，CD158A，Killer Cell Immunoglobulin-Like Receptor 2DL1，P58 NK Cell Inhibitory Receptor NKR-K6，Killer Inhibitory Receptor 2-2-1，KIR2DL Protein，CD158a Antigen，KIR2DL1/3DL2，KIR-K64，KIR221，P58.1，NKAT，Receptors， KIR2DL1，Cl-42 |
| Anzahl der inverkehr gebrachten Arzneimittel | 0 |
| Anzahl der klinischen Arzneimittel | 1 |
| Höchste Forschungs- und Entwicklungsphase | Phase 2 Clinical |
KIR2DL1 Produktliste
- Attribut
Protein (1)
- Produktbibliothek
Online (1)
- Spezies
Human (1)
- Etikett
Fc Tag (1)
- Marker
Unconjugated (1)
| Produktnummer | Spezies | Expressionssystem | Produktbeschreibung | Proteinstruktur | Reinheit | Eigenschaften | Vorbestellen/Bestellen |
|---|---|---|---|---|---|---|---|
 Human | HEK293 | Human KIR2DL1 / CD158a / NKAT-1 Protein, Fc Tag |  |  |  |  In den Warenkorb legen |
Gesamtmenge1
- 1
KIR2DL1 Molekülhintergrund
Killer cell immunoglobulin-like receptor 2DL1(KIR2DL1), which belongs to the immunoglobulin superfamily, is an inhibitory receptor of NK cells. Regulation of NK cell activity is mediated through killer-cell immunoglobulin-like receptors (KIR) ability to recognize human leukocyte antigen (HLA) class I molecules as ligands. Interaction of KIR and HLA is implicated in viral infections, autoimmunity, and reproduction and there is growing evidence of the coevolution of these two independently segregating gene families. Association of KIR2DL1 with β-arrestin 2 mediated recruitment of the tyrosine phosphatases SHP-1 and SHP-2 to KIR2DL1 and facilitated downstream inhibitory signaling.
KIR2DL1 Molekülalias
CD158a
Klinische Arzneimittelinformation
| Englischer Name | Forschungscode | Forschungsphase | Firma | Indikationen | Klinische Studie |
|---|---|---|---|---|---|
| Lirilumab | IPH-21; NN-1975; IPH-2101; IPH-2102; BMS-986015 | Phase 2 Clinical | Novo Nordisk A/S | Bone Marrow Neoplasms; Hodgkin Disease; Leukemia; Leukemia, Biphenotypic, Acute; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Multiple Myeloma; Neoplasms; Smoldering Multiple Myeloma; Squamous Cell Carcinoma of Head and Neck; Urinary Bladder Neoplasms | Details |
- Molekülinformation
- Produktliste
- Klinische Arzneimittelinformation